Disease · MONDO_0006964
Comparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 50
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cinacalcet vs Etelcalcetide: serious adverse events | 93 of 341 | 85 of 338 | 679 | NCT01896232 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: deaths from any cause | 9 of 317 | 4 of 320 | 637 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study | 15 of 315 | 35 of 318 | 633 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: serious adverse events | 61 of 315 | 53 of 318 | 633 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study | 61 of 310 | 109 of 317 | 627 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study | 194 of 310 | 241 of 317 | 627 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study | 245 of 310 | 273 of 317 | 627 | NCT03299244 | Trial comparisons |
| Cinacalcet vs Standard of Care: Number of Participants With Mean Serum Ca < 9.5 mg/dL | 281 of 368 | 61 of 184 | 552 | NCT00110890 | Trial comparisons |
| Cinacalcet vs Standard of Care: Number of Participants With Mean Serum P < 5.5 mg/dL | 231 of 368 | 92 of 184 | 552 | NCT00110890 | Trial comparisons |
| Cinacalcet vs Standard of Care: Number of Participants With Mean Ca x P < 55 mg^2/dL^2 | 282 of 368 | 106 of 184 | 552 | NCT00110890 | Trial comparisons |
| Cinacalcet vs Standard of Care: Number of Participants With Mean PTH ≤ 300 pg/mL | 262 of 368 | 41 of 184 | 552 | NCT00110890 | Trial comparisons |
| Cinacalcet vs Standard of Care: Number of Participants With Mean Ca x P < 55 mg^2/dL^2 and iPTH ≤ 300 pg/mL | 217 of 368 | 29 of 184 | 552 | NCT00110890 | Trial comparisons |
| Cinacalcet vs Standard Care: serious adverse events | 83 of 365 | 31 of 182 | 547 | NCT00110890 | Trial comparisons |
| Etelcalcetide vs Placebo: serious adverse events | 62 of 252 | 71 of 259 | 511 | NCT01788046 | Trial comparisons |
| Etelcalcetide vs Placebo: serious adverse events | 68 of 251 | 78 of 254 | 505 | NCT01785849 | Trial comparisons |
| Cinacalcet vs Control Group: serious adverse events | 88 of 180 | 82 of 180 | 360 | NCT00379899 | Trial comparisons |
| Paricalcitol vs Maxacalcitol: serious adverse events | 10 of 127 | 15 of 128 | 255 | NCT01341782 | Trial comparisons |
| Cinacalcet vs Control: Number of Participants Achieving > 15% Progression of CAC. | 63 of 115 | 77 of 120 | 235 | NCT00379899 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 0 of 108 | 3 of 108 | 216 | NCT01071070 | Trial comparisons |
| Sugar Pill to CTAP101 30 μg vs CTAP101 30 μg Capsules: Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D | 5 of 72 | 120 of 144 | 216 | NCT01704079 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006964/comparisons